464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)

Janet Graham(Beatson West of Scotland Cancer Centre), Jonathan J. Evans(Beatson West of Scotland Cancer Centre), Kristen K. Ciombor(The Ohio State University), Andrew L. Coveler(University of Washington), Sarah P. Blagden(Churchill Hospital), Francesca Aroldi(Churchill Hospital), Lisa Rodgers(Beatson West of Scotland Cancer Centre), Jordan Berlin(Dana-Farber Cancer Institute)
Annals of Oncology
September 1, 2020
10.1016/j.annonc.2020.08.575
Cited by 1

Related Papers

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2017|407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371